BUDGET IMPACT ANALYSIS OF ALEMTUZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN HEALTHCARE SOCIAL SECURITY (ESSALUD) IN PERU

被引：0
|
作者：
Moreno, M. [1 ]
Arce, J. [1 ]
Cruz, A. [2 ]
Carpio Farro, R. [3 ]
机构：
[1] Sanofi Aventis Colombia, Bogota, Cun, Colombia
[2] Hosp Alberto Sabogal, Magdalena Del Mar, Peru
[3] Sanofi Aventis Peru, Lima, Peru
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND37
引用
收藏
页码：S265 / S265
页数：1
相关论文
共 50 条
  • [41] Sustained Positive Effects of Alemtuzumab on Diverse Neurological Functions in Relapsing-Remitting Multiple Sclerosis Patients
    Fox, Edward
    NEUROLOGY, 2010, 74 (09) : A417 - A418
  • [42] Treatment with alemtuzumab after fingolimod in relapsing-remitting multiple sclerosis is effective and safe
    Alcala, C.
    Gascon, F.
    Perez-Miralles, F.
    Dominguez, J. A.
    Garcia Gil-Perotin, S.
    Casanova, B.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 274 - 274
  • [43] Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
    Zhang, Jian
    Shi, Shengliang
    Zhang, Yueling
    Luo, Jiefeng
    Xiao, Yousheng
    Meng, Lian
    Yang, Xiaobo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (11):
  • [44] Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis
    Rosario Blasco, Maria
    Ramos, Antonio
    Garcia Malo, Celia
    Garcia-Merino, Antonio
    JOURNAL OF NEUROLOGY, 2017, 264 (01) : 168 - 169
  • [45] Cerebral toxoplasmosis in patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab
    Raquel, Calle-Calle
    Lucia, Triguero-Cueva
    Carmen, Valderrama-Martin
    Ana, Romero-Villarrubia
    Antonio, Tapia-Gomez
    Juan, Pasquau-Liano
    Carmen, Arnal-Garcia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
  • [46] Alemtuzumab/fingolimodSevere activation of relapsing-remitting multiple sclerosis: 3 case reports
    Reactions Weekly, 2018, 1714 (1) : 25 - 25
  • [47] Immunogenicity of alemtuzumab treatment for relapsing-remitting multiple sclerosis: no effect on efficacy or safety
    Selmaj, K.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S247 - S247
  • [48] A BUDGET IMPACT ANALYSIS OF CLADRIBINE IN ENGLAND AND WALES FOR PATIENTS WITH HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (HA-RRMS)
    Herbert, A.
    Ashton, L.
    Alexopoulos, S. T.
    VALUE IN HEALTH, 2023, 26 (12) : S119 - S119
  • [49] Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis
    Omerzu, Tomaz
    Magdic, Jozef
    Hojs, Radovan
    Potocnik, Uros
    Gorenjak, Mario
    Fabjan, Tanja Hojs
    WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 (1-2) : 40 - 47
  • [50] Screening for dysphagia in patients with relapsing-remitting multiple sclerosis
    Kocica, Jan
    Lasotova, Nadezda
    Kolcava, Jan
    Svobodova, Monika
    Hladikova, Magdalena
    Stourac, Pavel
    Bednarik, Josef
    Vlckova, Eva
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 83
12345